• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer.

作者信息

Recondo Gonzalo, Mezquita Laura

机构信息

Medical Oncology, Precision Medicine Unit, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aires, Argentina.

Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona 08036, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spainz.

出版信息

Lancet Oncol. 2022 Jun;23(6):695-697. doi: 10.1016/S1470-2045(22)00261-3.

DOI:10.1016/S1470-2045(22)00261-3
PMID:35654050
Abstract
摘要

相似文献

1
Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer.替雷利珠单抗与阿替利珠单抗用于PD-L1阳性非小细胞肺癌患者的研究
Lancet Oncol. 2022 Jun;23(6):695-697. doi: 10.1016/S1470-2045(22)00261-3.
2
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.一项在转移性多器官癌患者中联合使用阿替利珠单抗、替西木单抗和立体定向体部放疗的 I 期研究。
BMC Cancer. 2023 Nov 9;23(1):1080. doi: 10.1186/s12885-023-11534-6.
3
[Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression].阿替利珠单抗用于一线治疗高程序性死亡配体1（PD-L1）表达的非小细胞肺癌
Bull Cancer. 2021 Oct;108(10):904-906. doi: 10.1016/j.bulcan.2021.06.011. Epub 2021 Sep 29.
4
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.SP142 和 22C3 免疫组化 PD-L1 检测用于评估非小细胞肺癌患者接受阿特珠单抗疗效的比较：来自 OAK 随机临床试验的结果。
Clin Lung Cancer. 2022 Jan;23(1):21-33. doi: 10.1016/j.cllc.2021.05.007. Epub 2021 May 30.
5
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.阿特珠单抗单药治疗转移性非小细胞肺癌的安全性和临床活性：I 期研究的最终结果。
Eur J Cancer. 2018 Sep;101:201-209. doi: 10.1016/j.ejca.2018.06.031. Epub 2018 Aug 1.
6
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌（IMpower010）：一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
7
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.非小细胞肺癌中使用程序性死亡1和程序性死亡配体1抑制剂后肺炎的发生率：试验的系统评价和荟萃分析
Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.
8
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.FIR：在 PD-L1 选择的 NSCLC 患者中进行的 Atezolizumab Ⅱ期开放标签研究的疗效、安全性和生物标志物分析。
J Thorac Oncol. 2018 Nov;13(11):1733-1742. doi: 10.1016/j.jtho.2018.05.004.
9
Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.经治非小细胞肺癌患者中PD-1/PD-L1抑制剂（纳武利尤单抗、帕博利珠单抗和阿特珠单抗）的比较：来自贝叶斯网络模型的证据
Int J Cancer. 2018 Dec 1;143(11):3038-3040. doi: 10.1002/ijc.31733. Epub 2018 Sep 25.
10
Tiragolumab active in PD-L1 NSCLC.替雷戈鲁单抗在PD-L1非小细胞肺癌中具有活性。
Nat Rev Clin Oncol. 2022 Jul;19(7):428. doi: 10.1038/s41571-022-00650-0.

引用本文的文献

1
Outcomes of primary CNS lymphoma treated with combined immunochemotherapy with whole-brain radiotherapy.采用联合免疫化疗及全脑放疗治疗原发性中枢神经系统淋巴瘤的疗效
Ann Hematol. 2025 Aug 25. doi: 10.1007/s00277-025-06561-1.
2
Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy.替雷利珠单抗与TIGIT：开创癌症免疫治疗的新时代。
Front Pharmacol. 2025 Jun 11;16:1568664. doi: 10.3389/fphar.2025.1568664. eCollection 2025.
3
Single-cell transcriptomics reveals the interaction between fibroblasts and activated immune cells: an exploratory bioinformatics study of pro-inflammatory mechanisms in slow transit constipation.
单细胞转录组学揭示成纤维细胞与活化免疫细胞之间的相互作用：慢传输型便秘促炎机制的探索性生物信息学研究
Int J Surg. 2025 Jun 1;111(6):3767-3780. doi: 10.1097/JS9.0000000000002415. Epub 2025 Apr 22.
4
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer.癌症中靶向PD-1/PD-L1的多特异性抗体
BioDrugs. 2025 May;39(3):427-444. doi: 10.1007/s40259-025-00712-6. Epub 2025 Mar 19.
5
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer.错配修复功能完整/微卫星稳定转移性结直肠癌免疫检查点抑制剂治疗的进展
Onco Targets Ther. 2024 Dec 24;17:1223-1253. doi: 10.2147/OTT.S500281. eCollection 2024.
6
Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.肿瘤微环境中的固有免疫细胞：癌症免疫治疗的新前沿。
iScience. 2024 Aug 17;27(9):110750. doi: 10.1016/j.isci.2024.110750. eCollection 2024 Sep 20.
7
The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.安罗替尼联合依托泊苷和顺铂/卡铂一线治疗肺癌的疗效和安全性：一项II期临床研究
J Cancer. 2024 May 5;15(11):3539-3546. doi: 10.7150/jca.91701. eCollection 2024.
8
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.一种新型的抗 LAG-3/TIGIT 双特异性抗体在作为单药或与 PD-1 抗体联合治疗的小鼠模型中显示出强大的抗肿瘤疗效。
Sci Rep. 2024 May 9;14(1):10661. doi: 10.1038/s41598-024-61477-6.
9
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.靶向TIGIT进行癌症免疫治疗：最新进展与未来方向
Biomark Res. 2024 Jan 16;12(1):7. doi: 10.1186/s40364-023-00543-z.
10
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors.组合阻断癌症免疫疗法：针对新兴免疫检查点受体。
Front Immunol. 2023 Oct 19;14:1264327. doi: 10.3389/fimmu.2023.1264327. eCollection 2023.